Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

the control group at 51% (p(less than or =)0.05). There was no statistically significant difference between PolyHeme and control patients for the other efficacy endpoints. -0-



                               TABLE 2

                           DAY 1 MORTALITY



                                        PolyHeme        Control

                                       (deaths/N)  %   (deaths/N)  %

 ------------------------------------- ---------- ---- ---------- ----

 MITT                                   34/350    9.7   27/364    7.4

 ------------------------------------- ---------- ---- ---------- ----

 AT                                     33/349    9.5   28/365    7.7

 ------------------------------------- ---------- ---- ---------- ----

 PP                                     20/279    7.2   21/307    6.8

 ------------------------------------- ---------- ---- ---------- ----

Safety Analysis

The primary safety endpoints in the study were Day 1 mortality, Day 30 mortality, and durable serious adverse events (SAEs). Durable serious adverse events were prospectively defined as SAEs which resulted in a "permanently disabling" outcome. There were two durable SAEs in each group. There was no statistically significant difference between the PolyHeme and control groups for any of these endpoints.

Additional Safety Data

All adverse events (AEs), serious adverse events (SAEs), cardiac SAEs, and myocardial infarction (MI) were also analyzed. The overall incidence of AEs in the PolyHeme group of 93% (324 patients) was higher than that in the control group of 88% (322 patients), (p(less than or =)0.05). The most common AEs in both groups were: anemia, fever, and electrolyte imbalances. The overall incidence of SAEs in the study was 40% (141 patients) in the PolyHeme group and 35% (126 patients) in the control group (pgreater than or 0.05). The most common SAEs in both groups were: shock, pneumonia, and respiratory failure.


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:9/16/2014)... ORLANDO, Fla. , Sept. 16, 2014   ... standard in the patient experience at hospitals. The myComfort™ ... , Vestagen,s active barrier fabric that is fluid repellant, ... shown to inhibit the growth of bacteria on the ... the role clothing plays in the chain of transmission. ...
(Date:9/16/2014)... , Sept. 16, 2014  Synereca ... developing novel orally active drugs that restore ... announced today a $1.4 million convertible debt ... of life sciences accelerator Accele Biopharma, Inc., ... Inc., a nationally recognized private not-for-profit corporation ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
... at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, ... PARD ), a biopharmaceutical company focused on oncology, ... March 31, 2009, and provided a corporate update. "The ... trial of picoplatin for the second-line treatment of small ...
... Two Studies at PAS Suggest Food Variety and ... of Affected ChildrenCINCINNATI, May 5 The strong ... places them at risk for nutritional deficiencies because ... from Cincinnati Children,s Hospital Medical Center at this ...
Cached Medicine Technology:Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 2Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 3
(Date:9/16/2014)... (HealthDay News) -- Although magnesium sulfate is routinely given ... new research suggests it won,t provide any long-term benefits ... magnesium sulfate given to pregnant women, researchers in Australia ... or functional outcomes among those children when they were ... The new findings don,t negate the fact that the ...
(Date:9/16/2014)... one day be able to predict when and how ... functioning, thanks in part to new findings that researchers ... Society for Radiation Oncology,s 56th Annual Meeting on Tuesday, ... than 17,000 surveys completed by men diagnosed with prostate ... sexual symptoms changed following each type of treatment, and ...
(Date:9/16/2014)... 16, 2014 This year’s theme is ... Sustainable company Glen Mills, Pennsylvania, September 15, 2014- Holganix, ... of the fastest growing companies in the country, produces ... shrub, and tree health-care by naturally decreasing disease and ... Today it announced that it will hold its third ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... the first objective scientific way to diagnose major depression in ... levels of nine genetic indicators (known as "RNA markers") in ... respond to cognitive behavioral therapy, one of the most common ... therapy worked, Northwestern University researchers report. Depression affects nearly ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... aimed at opening the airways and reducing inflammation appears ... chronic obstructive pulmonary disease (COPD), especially those with asthma, ... received a combination of long-acting beta agonists and inhaled ... because of their breathing disorder, compared to people receiving ...
Breaking Medicine News(10 mins):Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3
... wildfire along the Georgia-Florida border is burning thousands of acres and ... down. ,Between 250 and 500 homes west of U.S. ... fire line was breached, Florida Highway Patrol Lt. Michael Burroughs said. ... of the roadway were still waiting to return. ,The ...
... on multivitamins. The research conducted by Americas prestigious National Cancer ... multivitamin tablets a week, can in fact increase their risk ... ,The researchers who published their work in ... followed 295,344 men who reported taking multivitamins more than seven ...
... has been awarded a record order worth over $1 million ... is the biggest ever order placed with a single fitness ... joint venture agreement between Talwalkar Better Value Fitness and Pantaloon ... centers in major retail malls across the country. ...
... Indian tradition, popular yoga guru Swami Ramdev urged the government ... overseas. ,"Since there are attempts to ... and yoga organizations should take measures to prevent it," Ramdev ... belongs to the entire country and humanity. Also yoga cannot ...
... termed as thrilling and relieving, after four tough years a ... 000 US dollars. ,Ryszard Kolbuc won a lawsuit ... him accident coverage after he got paralyzed, during work. The incident ... mosquito carrying the West Nile virus. ,The accident ...
... who are trained in a new communication method called ... lifestyle behaviors, according to a study. ... clinical trial in which they asked 91 families about ... study are in the May issue of Archives of ...
Cached Medicine News:Health News:Massive Wildfire Forces Evacuation of Hundreds of Home in Florida 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2Health News:Talking With Families may Help Prevent Childhood Obesity 2
... Small Volume Medication Mouthpiece 7FT O 2 ... ,These Sidestream® nebulizers are designed to provide maximum ... treatment with a fast treatment time. Each of ... tubing and a vent seal adapter for use ...
Nebulizer Adapter Kit 6"...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
Medicine Products: